AGR2 and LYPD3 as breast cancer targets

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer

Inhibiting the membrane receptor LYPD3 or its ligand AGR2 could treat endocrine therapy-resistant breast

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE